| Name | Title | Contact Details |
|---|
capSpire propels energy and commodity businesses forward by blending human ingenuity with deep market expertise to solve complex challenges. Our mission is to deliver transformative solutions that empower businesses to grow, scale, and succeed. With three integrated services—Advisory, Delivery, and Operations and Support—capSpire offers holistic solutions that start with strategy and carry clients seamlessly through to scale. What sets capSpire apart is our ability to connect every stage of the value chain, delivering tailored solutions that integrate technology, processes, and industry insight. From strategy consulting and technology implementation to operational excellence, we strive to ensure that every solution drives measurable impact and uncovers new growth opportunities. At capSpire, we dont just implement solutions; we become an extension of your team. We empower businesses to maximize their investments and push forward—confidently and strategically—into the future. Together, well power forward.
At Flow, AI isnt just a feature—its the core of everything we do. We are transforming the wholesale insurance industry by building a futuristic insurance brokerage where AI powers every aspect of the experience. With advanced AI features already live in production and actively used by our brokers, we are pioneering Wholesale 3.0, equipping brokers with cutting-edge tools to provide unparalleled service. We are creating an ecosystem of AI agents designed to streamline processes and enhance decision-making in the insurance landscape. The industry relies heavily on text—emails, files, and documents—making Generative AI a perfect fit for solving its challenges. Flow leverages AI to deliver meaningful insights, deep analysis, and white-glove support for every transaction, no matter the deal size. By combining human expertise with Platformless AI, we are bringing back the art of wholesale insurance while eliminating the need for outdated portals. In the past seven months, weve grown 250% month-over-month(!) and are forecasting even more massive growth. Were a Series A startup with over $20M raised from top investors like Lightspeed, MunichRe Ventures, and industry angels.
Starr Insurance is a prominent part of Starr Companies, a global insurance and investment organization founded in 1919 by Cornelius Vander Starr. Initially established as the first American-owned insurance agency in Shanghai, the company has grown to operate across six continents, becoming a significant player in the insurance industry. Starr Insurance offers a diverse range of products and services, including commercial property and casualty insurance, as well as specialty coverages such as aviation, marine, energy, and excess casualty insurance. The company serves a wide array of clients, including leading businesses in sectors like construction, maritime, energy, and aerospace. With its extensive global presence, Starr Insurance is well-equipped to provide comprehensive insurance solutions tailored to the needs of businesses worldwide.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.